Pulse Therapeutics is proud to announce its merger with ICHOR Vascular and the subsequent creation of Euphrates Vascular. For more information, contact CEO Sean Morris.

Press Release

ICHOR Percutaneous Reperfusion System

Euphrates Vascular announces FDA clearance of the ICHOR Reperfusion System 

St. Louis, Missouri – Euphrates Vascular (www.euphratesvascular.com), a company focused on the treatment of vascular occlusions, recently received 510(k) clearance for sale of its ICHOR Percutaneous Reperfusion System. ICHOR is a Percutaneous Reperfusion System designed to treat organized thrombus and embolic events in the peripheral vasculature. ICHOR is a “one size fits all” system that…

Read More

Pulse Therapeutics and ICHOR Vascular Merge to Form Euphrates Vascular

Company aimed at becoming a leader in the treatment of vascular occlusions St. Louis, Missouri – Euphrates Vascular (www.euphratesvascular.com) is a medical device company created via the merger between Pulse Therapeutics and ICHOR Vascular. Bringing together technological synergies and experienced team members, the Euphrates Vascular (EV) vision is to become the leader in the treatment…

Read More